^
    Back
    Association details:
    Biomarker:KRAS G12C
    Cancer:Colon Cancer
    Drug:Erbitux (cetuximab) (EGFR inhibitor) +
    Krazati (adagrasib) (KRAS G12C inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    09/21/2023
    Excerpt:
    Colon Cancer: SYSTEMIC THERAPY FOR ADVANCED OR METASTATIC DISEASE…Adagrasib + cetuximab (KRAS G12C mutation positive)…
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Phase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer

    Excerpt:
    ...- Histologically confirmed diagnosis of adenocarcinoma of the colon or rectum with KRASG12C mutation....
    Trial ID:
    NCT05722327